


STRUCTURED FOR PROGRESS



IR PRESENTATION

June 2026

SAFE HARBOR STATEMENT


Forward-looking statements involve risks.

This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.


It is not planned to update these forward-looking statements.

STRATEC AT A GLANCE

- Leading OEM player for automation solutions for the diagnostics industry and translational research
- Three decades of experience in highly regulated healthcare markets and growing technology pool
- Around 1.400 employees worldwide
 - Around 50% allocable to R&D
- Production sites in Germany (HQ), Switzerland, Hungary, Austria and in the United States
- High number of systems installed globally
 - Around 50,000 systems
- Sales of € 250.9 million in 2025
 - CAGR sales since IPO in 1998: ~12%
- Sales split 2025:
 - Systems 35%
 - Service parts and consumables 41%
 - Development and services 24%



SELECTED PRODUCTS



UNIQUE POSITION WITHIN THE VALUE CHAIN

STRATEC provides instrumentation, consumables, software and automation solutions

- OEM development and manufacturing
- Several thousand automated analyzer systems manufactured annually
- Wide range of intellectual property rights / broad technology pool

Long market lifecycles lead to longstanding partnerships


- Product lifecycles for a system typically in an area of 12 to 15 years
- Expanding installed base of systems
- Product enhancement and extension drives value / Life cycle management

Long-term contractual setup


- Milestone payments during development stage (linked to agreed development budget and development targets)
- Operating sales during series production stage - minimum volume commitment by partner, firm transfer price)
- Recurring sales from service parts & consumables

→ strong commitment by both partners

Shared responsibilities



Indicative revenue characteristics of an analyzer OEM project



ACTIVE IN FAST GROWING SEGMENTS

IVD MARKET SEGMENTS / IVD MARKET: ~90 BILLION USD

Focus on market segments with above average complexity and growth

Molecular Diagnostics

- Random access analyser systems (mid-to-high throughput)
- Smart consumables (multiplexing)
- POC devices (multiplexing) with smart consumables

Immunoassay

- Random access analyzer systems (mid-to-high throughput)
- Classic plastic consumables
- Smart consumables


Hematology & other routine testing

- Decentralized testing solutions
- Veterinary diagnostics
- Plastics


Further specialities / focus areas

- Immunohematology
- Complex Sample Processing
- Tissue Diagnostics
- Translational Research

IVD market by technologies



IVD market by product group



Source: MarketsandMarkets Research; own estimates

BENEFITTING FROM OUTSOURCING TREND

OUTSOURCED VS IN HOUSE INSTRUMENTATION MARKET

The majority of instrumentation equipment in the IVD market is still developed in-house by diagnostics companies.

Share of outsourced developments has already increased significantly over the last couple of years.

Trend of outsourcing towards specialized players set to continue, due to:

- Engineering of automation solutions often not core competence of diagnostics companies
- Shorter development timeframes due to already existent technology pools
- Guaranteed project budget and firm transfer prices
- Keeping up with regulatory developments easier for specialized players
- Structured processes in order to address end customer needs, such as ease of use, user experience, workflow efficiencies, remote access, serviceability and preventive maintenance

Proportion of outsourced instrumentation developments over time

Past



Ongoing paradigm shift even within the „blue chips“ towards outsourcing

STRONG RECURRING REVENUE BASE


Service parts and consumables (41% of sales)

- Maintenance parts
- Spare parts
- Classic plastic consumables (eg. Pipetting tips, reaction vessels)
- Smart consumables (highly complex cartridges; microfluidics, molding, mastering and coating technologies)

Fueled by growing installed base and increasing complexity

- Continuously growing number of active systems in the lab
- Strong upward trend in the average complexity of systems

Smart consumables



SIMOA™ 24-ASSAY DISC
Quanterix



VITEK® MS
Disposable target slide
bioMérieux

Service and spare parts




Peristaltic Pump
STRATEC

Classic consumables




Stackable Cuvette
STRATEC

Service Parts & Consumables sales as % of total sales



Sales split 2025



STRONG LONG-TERM CUSTOMER RELATIONSHIPS

A SELECTION OF STRATEC CUSTOMERS

GLOBAL TOP 20 IVD COMPANIES		Sales 2025 (USD billion)
1.	Roche	16.9
2.	Danaher	9.9
3.	Abbott	8.9
4.	Siemens Healthineers	4.7
5.	Thermo Fisher	4.7
6.	bioMerieux	4.0
7.	Sysmex	3.4
8.	Exact Sciences	3.2
9.	QuidelOrtho	2.7
10.	CH Werfen (Inova, IL, Biokit)	2.5
11.	Illumina	2.3
12.	Natera	2.3
13.	Becton Dickinson	1.8
14.	Hologic	1.8
15.	Shenzay Mindray	1.7
16.	Bio-Rad	1.6
17.	Revvity (formerly PerkinElmer)	1.4
18.	DiaSorin	1.4
19.	Diagnostica Stago	1.1
20.	Agilent	1.1

... And other technology pioneers



■ STRATEC customer ■ Not a STRATEC customer

Source: IVD News / non-public companies estimated / non-reported sector sales estimated

GLOBAL SET UP ALIGNED WITH CUSTOMERS

LOCATIONS OF THE STRATEC GROUP

Site overview

Birkenfeld, Germany



HQ, R&D, Instrumentation
Production, Sales

Budapest, Hungary



Instrumentation Production,
Sales

Anif, Austria



R&D, Consumables Production,
Sales

Beringen, Switzerland



Instrumentation Production

Cluj, Romania



R&D
(Software Dev.)

Ronkonkoma, US




R&D, Consumables Production,
Sales

New Delhi, India



Sales



Q1 2026 AT A GLANCE

HIGHLIGHTS AND ACHIEVEMENTS



Declines in **sales** and **profitability** in line with **intra-year planning**

Strong momentum in the **Systems business** continues with **double-digit growth** rate in Q1 2026.



As already predicted, **negative scale** and **product mix effects**, burdened **margin development** in Q1 2026

Significant **improvement** in **free cash flow** dynamics



Well-filled development pipeline and progress in **transferring projects to serial production**



2026 guidance confirmed

Expectation of a heavily **back-end-loaded year**, underpinned by corresponding **orders and customer order forecasts**

FINANCIAL REVIEW

Q1 2026 FINANCIALS AT A GLANCE¹

€ 000s	Q1 2026	Q1 2025	Change
Sales	53,426	60,363	-11.5 % (cc: -8.8%)
Adjusted EBITDA	4,691	9,305	-49.6%
Adjusted EBITDA margin (%)	8.8	15.4	-660 bps
Adjusted EBIT	691	5,363	-87.1%
Adjusted EBIT margin (%)	1.3	8.9	-760 bps
Adjusted consolidated net income	-1,110	3,155	n/a
Adjusted basic earnings per share (in €)	-0.09	0.26	n/a
Basic earnings per share IFRS (in €)	-0.14	0.12	n/a
Free Cash Flow	18,597	-8,329	n/a

bps = basis points

cc = at constant currency

¹To facilitate comparison, figures have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and reorganization expenses).

FINANCIAL REVIEW

ADJUSTMENTS Q1 2026

EBIT

€ 000s	Q1 2026	Q1 2025
Adjusted EBIT	691	5,363
Adjustments:		
PPA amortization	-556	-924
Other ¹	-239	-1,369
EBIT	-104	3,070

¹ Non-recurring items including one-off advisory expenses, fees, and reorganization expenses

Consolidated net income

€ 000s	Q1 2026	Q1 2025
Adjusted consolidated net income	-1,110	3,155
Adjusted earnings per share in € (basic)	-0.09	0.26
Adjustments:		
PPA amortization	-556	-924
Other ¹	-239	-1,369
Taxes	192	584
Consolidated net income	-1,713	1,446
Earnings per share in € (basic)	-0.14	0.12

¹ Non-recurring items including one-off advisory expenses, fees, and reorganization expenses

FINANCIAL REVIEW

SALES Q1 2026



Q1 2026 sales -8.8% yoy in constant currency to € 53.4 million (nominal: -11.5%)

- Double-digit growth rate with system sales in Q1/2026


- Decline in service parts and consumables sales due to logistics optimizations measures at customers
- Tough prior year base of comparison for Development & Service sales

cc = at constant currency

As of March 31

FINANCIAL REVIEW

ADJUSTED EBIT AND EBIT MARGIN Q1 2026



As of March 31

Q1 2026 adj. EBIT at € 0.7 million

Margin decline of 760 bps YoY to 1.3%

- Efficiency measures and structural changes

- Decreased share of high-margin spare parts and consumables

- Negative scale effects

€ 000s	Q1 2026	Q1 2025
Research and development expenses	-1,718	-2,242
Sales-related expenses	-3,261	-3,355
General administrative expenses	-5,561	-6,891
Income / Expenses from impairment of financial assets and contract assets	-103	-230
Other operating income and expenses	338	-250

FINANCIAL REVIEW

CASH FLOW AND NET DEBT Q1 2026

€ 000s	Q1 2026	Q1 2025	Change
Cash flow – operating activities	21,493	-3,153	n/a
Cash flow – investment activities	-2,896	-5,176	n/a
Cash flow – financing activities	-18,071	-22,408	n/a
Free cash flow	18,597	-8,329	n/a

€ 000s	Q1 2026	FY 2025	Change
Cash at end of period	23,740	23,056	+3.0%
Equity ratio (%)	57.9	55.7	+220 bps
Net debt	93,235	112,459	-17.1%

- **Strong Cash Flow dynamics** due to reduction in the elevated trade receivables position caused by strong end to the year 2025

€ 000s	Q1 2026	FY 2025
Inventories	114,474	113,185
Trade receivables	43,437	56,933
Trade payables	13,523	12,635

- **Investment ratio¹ at 5.4%** of sales and below projected corridor of 6.5% to 8.5%
- **Net debt / LTM EBITDA at 3.1x** (down from 3.3x at the end of FY 2025)


¹ Total investments in intangible and tangible assets in % of sales

FINANCIAL REVIEW


SALES BY OPERATING DIVISIONS FY 2025



Sales in € million



In % of total sales



As of December 31

cc= at constant currency

OUTLOOK

FINANCIAL GUIDANCE FOR FISCAL YEAR 2026



Consolidated sales for the 2026 financial year expected to grow in a medium to high single-digit percentage range on a constant-currency basis

As in prior years and based on current order forecasts from customers, sales volumes are expected to be significantly weighted toward the second half of the year

Adjusted EBIT margin at around the previous year's level (FY 2025: 10.0%)

Benefits of scale are expected to be partly to fully offset by rising input costs attributable to factors including the impact of geopolitical conflicts



Investments in tangible and intangible assets combined of around 6.5% to 8.5% of sales (FY 2025: 6.5%)

OUTLOOK

TARGETS FOR SALES AND ADJUSTED EBIT MARGIN 2028 / 2030^{1,2}

SALES TARGETS:

CAGR of 6.0% to 8.0% for the period 2025 to 2028

Assumptions

- Several products in an advanced ramp-up phase set to be main revenue driver
- Slight recovery in MDx system demand post pandemic disruptions
- Initial revenue contributions from early-stage product supplies as well as transitions to new product generations with higher average selling prices

CAGR of 10.0% to 12.0% for the period 2028 to 2030

Assumptions


- Continuously increasing revenue contributions from new product launches
- Dynamic growth with Service & Parts and Consumables as a result of growing installed base

System sales set to be the main growth driver over entire forecast period, followed by Service Parts & Services, while Development & Service sales are foreseen to return closer to historical share

MARGIN TARGETS:

Adjusted EBIT margin of at least 13.0% by 2028

Adjusted EBIT margin of at least 15.0% by 2030



¹ The forecast does not take into account any revenues from analyzer systems in an OEM setup where the product is already in development, but the terms of the supply agreement have not yet been finalized or the customer has not yet placed an order

² Sales growth rates at constant currency


OUTLOOK

LAUNCH PIPELINE DRIVING THE NEXT GROWTH PHASE

UPCOMING LAUNCHES OVER THE NEXT FOUR YEARS¹

Project L

- Successor product and next-generation fully automated immunoassay system for an existing customer
- Extends addressable market for customer due to wider throughput range as well as drop-in replacement
- Status: design transfer to series production



Project N

- MultiPlex molecular diagnostics system, including complex consumable for an exiting customer
- Designed for specific needs of highly decentralized testing environments
- Status: instrument design completed, assay development at customer ongoing



Project M

- Successor product and next-generation molecular system for an existing customer
- Designed for the specific needs of decentralized testing environments
- Status: design transfer to series production




Project H

- New fully automated high-sensitivity immunoassay system for new customer (high share of polymer-based consumables)
- Designed for centralized clinical labs and blood banks
- Status: Prototype design completed, assay development at customer ongoing




Project R

- Successor product family for an existing customer in the field of immunohematology
- Partly competitive win, as the entire product family is now with STRATEC for the first time
- Status: system verification & validation on customer side



Modules Business

- Complex pipetting system for next-generation sample pooler for use in donor settings
- Several modules (e.g. pipetting system, loading bays, liquid management modules) for a next-generation MDx system



OUTLOOK

MARKET TRENDS THROUGHOUT DIFFERENT APPLICATION SEGMENTS

OVERALL IVD MARKET GROWTH ~ Low to mid single-digit growth rates

Market Trends by Application¹

IMMUNOASSAY ↑

- Transfer of single molecule technologies into the clinical labs
- Breakthrough discoveries in neurodegenerative diseases triggers demand for diagnostic assays and therapy monitoring solutions
- Rising applications within proteomics

MOLECULAR →

- Ongoing trend toward decentralized testing options in the US
- Demand for instruments sales still held back by significant capacity build up throughout pandemic

COMPLEX SAMPLE PREP ↑

- Breakthrough discoveries in Genomics and Cell Therapy drives significant additional demand for complex and highly automated sample prep processes

HEMATOLOGY & OTHER ROUTINE TESTING →

- Higher level of commoditisation and corresponding pricing pressure¹


IMMUNO-HEMATOLOGY →

- Ongoing high demand for cost-effective and workflow optimized solutions

¹ In reference to market sub-segments where STRATEC is active

OUTLOOK

REBUILDING PROFITABILITY THROUGH BUSINESS EXCELLENCE



MARGIN TARGETS:

Adjusted EBIT margin of at least 13.0% by 2028

Adjusted EBIT margin of at least 15.0% by 2030

- Pricing measures
- Targeted portfolio optimizations
- Operational excellence
- Utilization & benefits of scale

- FX effects due to USD exposure
- Negative sales mix: growth in systems expected to outperform growth in service parts

CE = Commercial Excellence
 OE = Operational Excellence

CORPORATE SOCIAL RESPONSIBILITY



 **E**COLOGICAL RESPONSIBILITY

FOR A BETTER TOMORROW

- Global Environmental Policy outlines the guiding principles and minimum standards of our environmental strategy.
- Developed transition plan that outlines the strategic measures and steps required to achieve our climate goals



Signatory to the UN Global Compact of the United Nations

- **STRATEC reduced its total Scope 1 and 2 (market-based) emissions by 52% since 2019**

 **S**Ocial RESPONSIBILITY

TOWARDS PEOPLE AND SOCIETY

- Strong policies and measures to promote an open, tolerant and discrimination-free corporate culture
- Extensive occupational health/safety policies and programs
- Formulated goals for diversity and health/safety KPI's with corresponding monitoring

 **C**ORPORATE GOVERNANCE

AS A BASIS FOR TRUST AND TRANSPARENCY

- Compliance management system in place to assure compliance with all national/international legislation
- ESG Board in place to identify and manage risks/opportunities related to sustainability.



Climate targets¹ validated by the **Science Based Targets initiative (SBTi)** and thus consistency with the target set by the Paris Agreement of limiting global warming to 1.5°C.

¹ Short-term targets: Reduction of absolute greenhouse gas emissions in Scope 1, 2 and 3 by 50.4% by 2032 compared with the 2023 base year | Long-term targets: Reduction of absolute greenhouse gas emissions in Scope 1, 2 and 3 by 90% by 2045 compared with the 2023 base year | Net zero targets: STRATEC is committed to achieving net zero greenhouse gas emissions throughout its value chain by 2045

APPENDIX

FINANCIAL CALENDAR 2026

Annual General Meeting 2026

2026-06-23

Publication Half-Year Financial Report H1|2026

2026-08-14

Publication Quarterly Statement 9M|2026

2026-11-12

APPENDIX

KEY FIGURES AT A GLANCE¹


IFRS (€ million)	2020	2021	2022	2023	2024	2025
Sales	250.1	287.3	274.6	270.4	257.6	250.9
Adjusted EBIT	41.7	54.3	45.1	30.4	33.5	25.2
Adjusted EBIT margin (%)	16.7	18.9	16.4	11.2	13.0	10.0
Adjusted consolidated net income	35.2	45.1	34.7	19.0	20.5	14.2
Adjusted earnings per share (€)	2.92	3.73	2.86	1.56	1.69	1.17
Dividend per share (€)	0.90	0.95	0.97	0.55	0.60	0.60
No. of employees	1,319	1,398	1,481	1,522	1,450	1,403
Total assets	331.9	368.5	397.5	450.7	455.0	426.0
Equity ratio (%)	52.0	55.8	56.6	52.6	54.5	55.7
Free cash flow	10.0	43.3	-8.7	-24.7	33.7	-17.2

¹ For comparison purposes, adjusted figures have been adjusted to exclude amortization from purchase price allocations in the context of acquisitions, as well as for other one-off items (e.g. consulting and reorganization expenses in connection with M&A activities and one-off personnel expenses).

APPENDIX

SHAREHOLDER STRUCTURE

(AS OF: MAY 2026)



Institutional investors > 3%:

- Brown Capital Management
- Aalap Mahadevia / Briarwood Capital Partners LP
- Morgan Stanley
- JPMorgan Chase & Co.
- Juno Investment Partners

SHARE

IPO	Aug. 1998
Number of shares	12,157,841
Share price (May 28, 2026)	€ 16.48
Market capitalization	€ 200 million

CONTACT

STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany

Phone +49 7082 7916-0
Fax +49 7082 7916-999
www.strattec.com

CONTACT

Jan Keppeler, CFA
Head of Investor Relations, Sustainability & Corporate
Communications

Phone +49 7082 7916-6515
j.keppeler@strattec.com



THANK YOU
FOR YOUR
ATTENTION